PET and PET/CT in the Management of Thyroid Cancer
Methods in Molecular Biology, Humana Press Inc., ss.205-224, 2011
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2011
- Doi Numarası: 10.1007/978-1-61779-062-1_12
- Yayınevi: Humana Press Inc.
- Sayfa Sayıları: ss.205-224
- Anahtar Kelimeler: Differentiated thyroid carcinoma, Medullary carcinoma of thyroid, PET, PET-CT, Thyroid carcinoma, Thyroid lymphoma
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
The introduction of PET(-CT) has brought about a major paradigm shift in the management of thyroid carcinoma, especially from the diagnostic standpoint. From the viewpoint of patient management, the areas where it has made significant impact include the following: (1) the detection of disease focus in patients with differentiated thyroid carcinoma with elevated Tg levels and negative radioiodine scan. When localized disease is identified with F-18 FDG–PET-CT, surgery or focused radiotherapy could be utilized to eradicate the tumor; (2) the localization of disease in patients of MTC with elevated serum calcitonin levels; (3) the detection of unsuspected focal F-18 FDG uptake in the thyroid in patients undergoing whole body F-18 FDG PET for a different indication. This would prompt a workup to rule out thyroid carcinoma. The use of I-124 is evolving at this time and has been of great promise with regard to (a) its better efficacy of lesion detection and (b) the ability to provide lesion-specific dosimetry. In addition, F-18 FDG PET appears to be of potential value in patients with thyroid lymphoma in making the initial diagnosis, monitoring therapeutic response, and assessing for residual disease and/or recurrence.